2007/08/28 by Klaus Rave, Tim Heise, Andreas Pfützner +3
Medicine · #Inhalation and Respiratory Drug Delivery #Pharmaceutical studies and practices #Diabetes Management and Research
paper · pdf · doi:10.2337/dc07-0478
T echnosphere Insulin (TI) is a formu-lation of regular human insulin(RHI) that provides efficient pulmo-nary administration (1) and demonstrates unique pharmacokinetic and pharmaco-dynamic properties compared with sub-cutaneous RHI, rapid-acting insulin analogs, and other inhaled insulins (2). Administration of TI results in a time to maximum insulin concentration of 15 min, with almost complete absorption within 3 h (3,4). With an onset of action comparable to intravenous insulin, TI represents the first formulation that ap-proaches the physiological early insulin release. In this study, we evaluated the efficacy and safety of TI compared with subcutaneous RHI in covering prandial insulin needs. We measured blood glu-cose excursions after a meal challenge af-ter individual titration of either insulin formulation during a 7-day treatment pe-riod in subjects with type 2 diabetes.